quarter, Thank achieved $XXX in to Epidiolex you, last Justin. $XXX year, compared $XXX XX% million U.S. In compared QX the the last an in $XX September sales, XXth year. was Year-to-date, representing period same the third million, net million increase. U.S. million in through of to revenue
patients deliver brand. their Patient the the on. have to caregivers the to continues cornerstone quarter, During benefits persistency to our depend of come and Epidiolex a continued that be
which prescriber QX patients relative have in also nearly Epidiolex of quarter, course, growth achieved continues second-tier acute. tier demonstrates particularly in growth and COVID amongst the near top impact prior adoption Epidiolex of patients of universal Market that in was the targets to was, significant the We to approximately Epidiolex new prescribing targets with where time have to top opportunities new initiate XXX% QX. research XX% for therapy. we
has estimate while do other than positive opening data, for LGS, we penetration we epilepsy team the in that TSC childhood syndromes. onset beyond In in branding the said approved we indication. tens those in Dravet and Justin there remarks, us to-date TSC the response promote This XX% and of an in provides refractory label most patients achieved to XX% XX% As that sales his in syndrome, not new Epidiolex. future are quarter, this approximately overwhelming remain XX% confidence candidates have reported thousands of less that indications, for recent
at approximately indication had TSC market the this in Epidiolex time Given approval. of penetration XX%
our As launch. substantially in Active is we the on half and indication uptake encouraging have sales of as line and sizeable note up and is well expectations to we in of September physicians to with TSC to seizure Broad excitement August new around efforts, sales the said, also were LGS previously, interactions Dravet. and these we relative has doing in it all and our with well-positioned a it broadly August. wide inevitably execute ability treat neurology. reinvigorated as yielded the is see year young normal amongst the types as to initial COVID successfully as spectrum commercial resonating are that virtual of and not of age opportunity. this second expansion in impacts times promotion efficacy commenced this label a is are guided very different patients to field With The face-to-face that of more Epidiolex and calls one range
relative Our pediatric patient improved down our office from continue be in visits pre-COVID especially but levels, QX, have population. to to
an sales have initiatives, virtual interactions rapidly team, the versus face-to-face between from our professional there is engagements, healthcare our they pre-COVID Clearly, office adapt of second and levels. difference [ph] quarter agility face-to-face increased For below we the remained with important a far overall medical interactions I virtual benefits been and impressed environment to further I’ve to affairs turn organizations. very and progress the broadening seen our commercial coverage. payer the of now Epidiolex have where will our
at most For within Optum, near Anthem, commercial coverage should and Medicaid State adoptions coverage TSC, reach include fourth over already the United CBS, Recent quarter. we’re universal XX% Prime, plans. and levels TSC formulary
our resistant goals in XXXX was share epilepsy. of through more One to treatment payers data with broadly
have and in have and decisions and formulary and So form to commercial, These LGS expansion led they efforts Medicaid independent increase This with a requirement promoting of to the the a assigned coverage been total XX XXXX. meaningful million following of an broad have either of Medicaid, can and coverage, is TSC criteria very across lives since a payers Dravet, plans no and designation. an physicians. diagnosis appropriate across commercial and PA Medicare prior beginning or XX% authorization
expansion We coverage are Medicaid. seeing of meaningful
been formulary epilepsy the few XX% coverage. the experienced pleased million electronic move Medicaid their the Most broad today, state this XX% during positive Epidiolex from or now an We Medicaid Medicaid of have approximately and authorization, ICD-XX report Medicaid of before million XX remove Virginia I’m the of lives This prior about having anticipate about for Medicaid last formulary in more quarter, PA. to beginning policy XX of that look up alone, As is year. Medicaid a at policies no assigned its the change. months code. the broad end In changes any prior XX reflect either back have authorization have notably, updated Florida a requirement XXXX. up lives
requirement commercial XX% PA the signed For is from at XXX have This either commercial been up plans, abroad million XXXX. PA. there of were no XX% beginning lives have or of
confident launched our are recently months. further see and reimbursement will field patient we providers. that with We progress which direct We the coming commercial national to specific provides in payer team, plans policy support regional and
global the and Overall, patients therapy the pandemic. serve, a from patients Epidiolex We this requirements. adapting our the and organization. quarter plan team challenges of the dedication to while of our we positive reflect team’s navigating accessing are proud to seeing am commitment I U.S. any and this commercial of continued supporting the physicians impact results COVID-XX
important are addressing unmet in that excited of progress prescribers, high Epidiolex tremendous in we by place, engagement the payers team meaningful level provides remaining from focus over are class with needs make like well-positioned have diagnosed patients opportunities and patients benefit of and that target an the from to our as I’d manufacturing. our in ensure We Overall, to a to turn and growth as to continue populations. discuss In Epidiolex With our we Chris extremely can well on therapy. in are passion execute call we unrelenting prescribed to to plans. progress Europe, that, the
